{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:41:40Z","timestamp":1777639300580,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["VIP+00560"],"award-info":[{"award-number":["VIP+00560"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helmholtz-Validierungsfonds","award":["HVF\u2010046"],"award-info":[{"award-number":["HVF\u2010046"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.nucmedbio.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,3,4]],"date-time":"2018-03-04T01:26:22Z","timestamp":1520126782000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Evaluation of 177Lu[Lu]-CHX-A\u2033-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII"],"prefix":"10.1016","volume":"60","author":[{"given":"L.","family":"Fiedler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gosewisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Oos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"B\u00f6ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"Reulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ijc.10233","article-title":"Clinical impact and functional aspects of tenascin-C expression during glioma progression","volume":"98","author":"Herold-Mende","year":"2002","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.nucmedbio.2018.02.004_bb0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/imt.13.43","article-title":"Radioimmunotherapy for high-grade glioma","volume":"5","author":"De Bonis","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1023309927635","article-title":"Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times","volume":"62","author":"Goetz","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00701-014-2271-x","article-title":"Anatomic features of glioblastoma and their potential impact on survival","volume":"157","author":"Nestler","year":"2015","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-007-0293-7","article-title":"Diffuse glioma growth: a guerilla war","volume":"114","author":"Claes","year":"2007","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2018.02.004_bb0040","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.bjc.6601771","article-title":"Targeted radiotherapy of brain tumors","volume":"90","author":"Zalutsky","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0045","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2014.12.JNS142168","article-title":"Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy","volume":"123","author":"Reulen","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0050","first-page":"182","article-title":"A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost","volume":"10","author":"Reardon","year":"2008","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2018.02.004_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131\u2013labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results","volume":"24","author":"Reardon","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2018.02.004_bb0060","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1200\/JCO.1998.16.6.2202","article-title":"Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results","volume":"16","author":"Bigner","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2018.02.004_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0360-3016(97)00486-0","article-title":"Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma","volume":"40","author":"Chang","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.nucmedbio.2018.02.004_bb0070","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2350::AID-CNCR20>3.0.CO;2-R","article-title":"Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy","volume":"88","author":"Madajewicz","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0075","doi-asserted-by":"crossref","DOI":"10.3171\/jns.1998.88.1.0001","article-title":"Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973\u20131991","volume":"88","author":"Davis","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.nucmedbio.2018.02.004_bb0085","first-page":"6494","article-title":"Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. American Association for Cancer Research","volume":"73","author":"Gondi","year":"2013"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00262-011-0980-z","article-title":"Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII","volume":"60","author":"Battke","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.apradiso.2016.05.025","article-title":"Evaluation of 177Lu-CHX-A\u2032\u2032-DTPA-bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers","volume":"114","author":"Kameswaran","year":"2016","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"10.1016\/j.nucmedbio.2018.02.004_bb0100","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-labeled antiTenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-004-0608-7","article-title":"Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats","volume":"54","author":"Goetz","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.nucmedbio.2018.02.004_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/10849780152389410","article-title":"Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results","volume":"16","author":"Paganelli","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"10.1016\/j.nucmedbio.2018.02.004_bb0115","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1158\/1078-0432.CCR-05-2820","article-title":"Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P","volume":"12","author":"Kneifel","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2018.02.004_bb0120","first-page":"580","article-title":"Imaging glioma extent with 131I-TM-601","volume":"46","author":"Hockaday","year":"2005","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2018.02.004_bb0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","article-title":"Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial","volume":"37","author":"Cordier","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.nucmedbio.2018.02.004_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.1983.1","article-title":"Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data","volume":"3","author":"Patlak","year":"1983","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.nucmedbio.2018.02.004_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3171\/jns.1977.46.1.0024","article-title":"Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema","volume":"46","author":"Reulen","year":"1977","journal-title":"J Neurosurg"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/bit.260220504","article-title":"Estimation of diffusion coefficients of proteins","volume":"22","author":"Young","year":"1980","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.elecom.2010.11.032","article-title":"Understanding the linear correlation between diffusion coefficient and molecular weight. A model to estimate diffusion coefficients in acetonitrile solutions","volume":"13","author":"Valencia","year":"2011","journal-title":"Electrochem Commun"},{"issue":"4","key":"10.1016\/j.nucmedbio.2018.02.004_bb0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0360-3016(97)00915-2","article-title":"Direct injection of 90Y Moabs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose","volume":"40","author":"Hopkins","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0160","first-page":"544","article-title":"An approach for conjugation of 177Lu-DOTA-SCN-Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients","volume":"139","author":"Thakral","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.nucmedbio.2011.02.009","article-title":"Preparation and biological evaluation of 177Lu conjugated PR81 for radioimmunotherapy of breast cancer","volume":"38","author":"Salouti","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0969-8051(02)00294-9","article-title":"In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications","volume":"29","author":"Milenic","year":"2002","journal-title":"Nucl Med Biol"},{"issue":"12","key":"10.1016\/j.nucmedbio.2018.02.004_bb0175","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2967\/jnumed.109.064444","article-title":"177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression","volume":"50","author":"Maddalena","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"},{"issue":"11","key":"10.1016\/j.nucmedbio.2018.02.004_bb0185","first-page":"1898","article-title":"89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab","volume":"46","author":"Perk","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jlcr.3140","article-title":"A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy","volume":"57","author":"Chakravarty","year":"2013","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0195","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jlcr.3413","article-title":"90Y\/177Lu-labelled cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation","volume":"59","author":"Chakravarty","year":"2016","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0200","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jrras.2016.07.001","article-title":"Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab')2-trastuzumab for theranostic agent of HER2 positive breast cancer","volume":"9","author":"Hermanto","year":"2016","journal-title":"J Radiat Res Appl Sci"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0205","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2967\/jnumed.114.149690","article-title":"89Zr-labeled versus 124I-labeled aHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo","volume":"56","author":"Mendler","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0210","series-title":"High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation","first-page":"96","author":"Mendler","year":"2015"},{"issue":"1","key":"10.1016\/j.nucmedbio.2018.02.004_bb0215","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2018.02.004_bb0220","first-page":"3969","article-title":"Pharmacokinetics of monoclonal immunoglobulin G1, F(ab\u2032)2, and Fab\u2032 in mice","volume":"46","author":"Covell","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0225","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"54","author":"Vegt","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2015.04.001","article-title":"In vivo imaging with antibodies and engineered fragments","volume":"67","author":"Freise","year":"2015","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2018.02.004_bb0235","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0240","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","article-title":"Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins","volume":"60","author":"Akizawa","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2018.02.004_bb0245","first-page":"829","article-title":"Intracellular fate of radiometals [letter to the editor]","volume":"38","author":"Duncan","year":"1997","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.nucmedbio.2018.02.004_bb0250","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2591::AID-CNCR35>3.0.CO;2-5","article-title":"Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates","volume":"80","author":"Behr","year":"1997","journal-title":"Cancer Suppl"},{"issue":"22","key":"10.1016\/j.nucmedbio.2018.02.004_bb0255","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.nucmedbio.2018.02.004_bb0260","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/002215540004801203","article-title":"Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors","volume":"48","author":"Parkkila","year":"2000","journal-title":"J Histochem Cytochem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117303360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117303360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T01:45:29Z","timestamp":1570844729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117303360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":51,"alternative-id":["S0969805117303360"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.02.004","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of 177Lu[Lu]-CHX-A\u2033-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}